ArticleBMC nephrology2025
Pregnancy outcomes in C3 glomerulopathy: a retrospective review.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does pregnancy modify disease activity in C3 glomerulopathy?CEN case reports · 2026Article
- Correction: Pregnancy outcomes in C3 glomerulopathy: a retrospective review.BMC nephrology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
backgroundC3 Glomerulopathy (C3G) is an ultra-rare glomerular disease driven by dysregulation of the alternative pathway of complement. 30-50% of adult patients progress to end stage kidney disease (ESKD) within 10 years of diagnosis. Little is known of the impact of pregnancy on the natural history of C3G or whether a coincident diagnosis of C3G affects maternal-fetal outcomes.
methodsFemale subjects from the University of Iowa's C3G Natural History Study who met consensus biopsy criteria were included if they had at least one pregnancy and available renal/obstetric data. Assessed data included clinical history, kidney function tests, and complement tests to identify genetic and/or acquired drivers of complement dysregulation. Appropriate t-tests or z-tests were used to compare outcomes and clinical biomarker changes pre-/post-pregnancy. Nonlinear regression and relative risk were used to estimate risk for preeclampsia, premature delivery, and progression to ESKD.
resultsAmongst mothers whose C3G presented before or during pregnancy (C3G + P), there were 37 pregnancies and 27 deliveries. Non-live birth outcomes impacted 10 C3G + P and included 5 spontaneous miscarriages, 1 stillbirth, 1 ectopic pregnancy, and 3 elective abortions. Twelve deliveries (44%) were premature, while 16 (59%) were associated with antepartum preeclampsia: an elevated risk when compared to healthy pregnancies and pregnancies of mothers with other glomerular diseases. Risk factors for complications included preexisting hypertension, an identified driver of complement dysregulation, and an eGFR prior to pregnancy of < 60 ml/min/1.73m
conclusionsA C3G + P is associated with increased risk of preeclampsia and prematurity compared to healthy controls, but no excess risk of spontaneous miscarriage. A C3G + P was associated with a small but significant decrease in renal function as measured by change in creatinine and eGFR. The elevated risk of adverse renal and obstetric events supports the need for multidisciplinary care for expectant patients with C3G.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.